Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Cancer Cell(2022)10.1016/j.ccell.2022.02.017Source: DataRank Database

Expanding the immunotherapy roadmap for hepatocellular carcinoma is a research paper published in Cancer Cell (2022). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.37)OA: bronzeTopics (23)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Amy K. Kim ORCID,Robert A. Anders ORCID,Marina Baretti ORCID

Live enrichment

PubMed:35290785 PMC:PMC9844534 OpenAlex:https://openalex.org/W4220997720

NCI NIH HHS

Grant: P30 CA006973

National Institutes of Health

Bristol-Myers Squibb

AstraZeneca

FWCI

1.37

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.cell.com/article/S1535610822000691/pdf

publisherhttp://www.cell.com/article/S1535610822000691/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535610822000691?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610822000691?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2022.02.017

Fields of Study

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersHepatitis B Virus Studies

MeSH Terms

SorafenibNivolumabCarcinoma, HepatocellularHumansImmunologic FactorsImmunotherapyLiver Neoplasms

Keywords

SorafenibHepatocellular carcinomaNivolumabImmunotherapyMedicineInternal medicineOncologyTyrosine-kinase inhibitorCarcinomaCancer researchTyrosine kinaseCancerReceptor

Sustainable Development Goals

SDG 0: Good health and well-being